Not yet recruitingPhase 1NCT07492316

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

Studying Medulloblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Florida
Principal Investigator
Sabine Mueller, MD, PhD
University of California, San Francisco
Intervention
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)(biological)
Enrollment
24 target
Eligibility
4-39 years · All sexes
Timeline
2026 – 2031

Collaborators

Pediatric Neuro-Oncology Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07492316 on ClinicalTrials.gov

Other trials for Medulloblastoma

Additional recruiting or active studies for the same condition.

See all trials for Medulloblastoma →

← Back to all trials